These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 38413778)

  • 1. Characterizing emerging companies in computational drug development.
    Markey C; Croset S; Woolley OR; Buldun CM; Koch C; Koller D; Reker D
    Nat Comput Sci; 2024 Feb; 4(2):96-103. PubMed ID: 38413778
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Early achievements of the Danish pharmaceutical industry--8. Lundbeck].
    Grevsen JV; Kirkegaard H; Kruse E; Kruse PR
    Theriaca; 2016; (43):9-61. PubMed ID: 27491172
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 4. State-of-the-art and dissemination of computational tools for drug-design purposes: a survey among Italian academics and industrial institutions.
    Artese A; Alcaro S; Moraca F; Reina R; Ventura M; Costantino G; Beccari AR; Ortuso F
    Future Med Chem; 2013 May; 5(8):907-27. PubMed ID: 23682568
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [An analysis of the pharmaceuticals market in Vietnam].
    Simonet D
    Sante; 2001; 11(3):155-60. PubMed ID: 11641078
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adverse Drug Reaction Case Safety Practices in Large Biopharmaceutical Organizations from 2007 to 2017: An Industry Survey.
    Stergiopoulos S; Fehrle M; Caubel P; Tan L; Jebson L
    Pharmaceut Med; 2019 Dec; 33(6):499-510. PubMed ID: 31933240
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Equipment and analytical companies meeting continuous challenges. May 20-21, 2014 Continuous Manufacturing Symposium.
    Page T; Dubina H; Fillipi G; Guidat R; Patnaik S; Poechlauer P; Shering P; Guinn M; Mcdonnell P; Johnston C
    J Pharm Sci; 2015 Mar; 104(3):821-31. PubMed ID: 25448273
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quantitative Analysis for Chinese and US-listed Pharmaceutical Companies by the LightGBM Algorithm.
    Zheng W; Li J; Wang Y; Ye Z; Zhong H; Kot HW; Ouyang D; Chan G
    Curr Comput Aided Drug Des; 2023; 19(6):405-415. PubMed ID: 36703589
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quantum computing's potential for drug discovery: Early stage industry dynamics.
    Zinner M; Dahlhausen F; Boehme P; Ehlers J; Bieske L; Fehring L
    Drug Discov Today; 2021 Jul; 26(7):1680-1688. PubMed ID: 34119668
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systematic risk identification and assessment using a new risk map in pharmaceutical R&D.
    Schuhmacher A; Brieke C; Gassmann O; Hinder M; Hartl D
    Drug Discov Today; 2021 Dec; 26(12):2786-2793. PubMed ID: 34229082
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Critical analysis of valuation and strategical orientation of merger and acquisition deals in the pharmaceutical industry.
    Dierks RML; Bruyère O; Reginster JY
    Expert Rev Pharmacoecon Outcomes Res; 2018 Apr; 18(2):147-160. PubMed ID: 29243501
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stock price reaction to the drug development setbacks in the pharmaceutical industry.
    Abramavičius S; Stundžienė A; Korsakova L; Venslauskas M; Stankevičius E
    Daru; 2021 Jun; 29(1):1-11. PubMed ID: 33539000
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Industry funding of patient organisations in the UK: a retrospective study of commercial determinants, funding concentration and disease prevalence.
    Gentilini A; Parvanova I
    BMJ Open; 2023 Jun; 13(6):e071138. PubMed ID: 37369404
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Drug Discovery and Development Industry in India-Two Decades of Proprietary Small-Molecule R&D.
    Differding E
    ChemMedChem; 2017 Jun; 12(11):786-818. PubMed ID: 28464443
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potential Use of Artificial Intelligence for Regulatory Intelligence: Biopharmaceutical Industry's Views.
    Mayer M; Canedo A; Dinh T; Low M; Ortiz A; Garay C
    Ther Innov Regul Sci; 2019 Nov; 53(6):759-766. PubMed ID: 30522348
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cross-company collaboration to leverage analytics for clinical quality and accelerate drug development: The IMPALA industry group.
    Ménard T; Young K; Siegel L; Emerson J; Studt R; Sidor L;
    CPT Pharmacometrics Syst Pharmacol; 2021 Aug; 10(8):799-803. PubMed ID: 34247450
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Setbacks and promises for drugs against Alzheimer's disease: As pharmaceutical companies are retreating from drug development for Alzheimer's, new approaches are being tested in academia and biotech companies.
    Rinaldi A
    EMBO Rep; 2018 Sep; 19(9):. PubMed ID: 30150324
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Scientific diligence for oncology drugs: a pharmacology, translational medicine and clinical perspective.
    Parasrampuria DA; Bandekar R; Puchalski TA
    Drug Discov Today; 2020 Oct; 25(10):1855-1864. PubMed ID: 32693162
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prediction and visualization of Mergers and Acquisitions using Economic Complexity.
    Arsini L; Straccamore M; Zaccaria A
    PLoS One; 2023; 18(4):e0283217. PubMed ID: 37011046
    [TBL] [Abstract][Full Text] [Related]  

  • 20. How is the Pharmaceutical Industry Structured to Optimize Pediatric Drug Development? Existing Pediatric Structure Models and Proposed Recommendations for Structural Enhancement.
    Severin T; Corriol-Rohou S; Bucci-Rechtweg C; An Haack K; Fuerst-Recktenwald S; Lepola P; Norjavaara E; Dehlinger-Kremer M; ; Haertter S; Cheung SYA;
    Ther Innov Regul Sci; 2020 Sep; 54(5):1076-1084. PubMed ID: 32030690
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.